

# Ignacio Garrido-Laguna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8269842/publications.pdf>

Version: 2024-02-01

121  
papers

7,479  
citations

147801

31  
h-index

56724

83  
g-index

121  
all docs

121  
docs citations

121  
times ranked

12187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1&2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
2	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	4.9	758
3	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 359-369.	4.9	675
4	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	27.6	489
5	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	1.6	414
6	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1311-1316.	4.1	354
7	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	4.1	311
8	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 806-815.	4.9	310
9	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	27.6	244
10	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 3-8.	4.1	238
11	Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5793-5800.	7.0	204
12	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2545-2556.	1.6	204
13	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	2.5	174
14	TIGIT: a novel immunotherapy target moving from bench to bedside. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1659-1667.	4.2	152
15	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	1.6	151
16	Novel Therapeutic Targets in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1601-1612.	1.1	127
17	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. <i>Cancer Biology and Therapy</i> , 2011, 12, 598-609.	3.4	103
18	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1109-1133.	4.9	92

#	ARTICLE	IF	CITATIONS
19	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	4.1	88
20	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	1.8	79
21	Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. <i>Journal of Clinical Oncology</i> , 2010, 28, e633-e636.	1.6	77
22	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. <i>British Journal of Cancer</i> , 2010, 103, 649-655.	6.4	65
23	Genomically Driven Tumors and Actionability across Histologies: <i>BRAF</i> -Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 533-547.	4.1	63
24	A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 1257-1264.	2.6	59
25	KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. <i>PLoS ONE</i> , 2012, 7, e38033.	2.5	44
26	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	1.8	44
27	Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-Based Study in Utah. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2078-2084.e2.	4.4	42
28	Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1014-1026.	1.4	42
29	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. <i>Cancer</i> , 2017, 123, 3816-3824.	4.1	35
30	First-in-human, phase I study of PF-06647263, an anti-VEGFA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 1798-1808.	5.1	34
31	Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4015-4015.	1.6	34
32	Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	3.0	32
33	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	2.0	30
34	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019, 24, 219-228.	3.7	30
35	Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 355-362.	1.3	30
36	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	4.1	27

#	ARTICLE	IF	CITATIONS
37	Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.. Journal of Clinical Oncology, 2018, 36, 521-521.	1.6	27
38	A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014, 1, 614-623.	2.2	26
39	New scaffolds for the design of selective estrogen receptor modulators. Organic and Biomolecular Chemistry, 2008, 6, 3486.	2.8	24
40	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646.	2.6	24
41	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research, 2021, 27, 6314-6322.	7.0	22
42	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2017, 8, 387-404.	1.4	21
43	Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 2018, 3, e000282.	4.5	21
44	Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.. Journal of Clinical Oncology, 2016, 34, 3020-3020.	1.6	21
45	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 478-482.	4.9	21
46	Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2017, 24, 4001-4008.	1.5	20
47	A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist, 2021, 26, e1844-e1853.	3.7	18
48	Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer. Cancer Research, 2018, 78, CT124-CT124.	0.9	18
49	The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology, 2011, 8, 562-566.	27.6	17
50	Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Investigational New Drugs, 2019, 37, 482-489.	2.6	17
51	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	7.0	16
52	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment. Clinical Cancer Research, 2010, 16, 4031-4037.	7.0	15
53	Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Reports, 2020, 32, 107994.	6.4	15
54	O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Annals of Oncology, 2020, 31, 232-233.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 452-452.	1.6	14
56	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. <i>Discovery Medicine</i> , 2015, 19, 109-16.	0.5	13
57	The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. <i>Cancer Medicine</i> , 2020, 9, 1703-1711.	2.8	12
58	Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. <i>ESMO Open</i> , 2018, 3, e000386.	4.5	11
59	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2517-2517.	1.6	10
60	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. <i>Future Oncology</i> , 2018, 14, 947-962.	2.4	9
61	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.	1.7	9
62	Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic. <i>Oncologist</i> , 2011, 16, 327-335.	3.7	8
63	Large database utilization in health outcomes research in pancreatic cancer: an update. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 996-1004.	1.4	8
64	Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 663-675.	1.5	8
65	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. <i>Discovery Medicine</i> , 2014, 18, 331-9.	0.5	8
66	Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). <i>Annals of Oncology</i> , 2019, 30, iv134.	1.2	7
67	Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1401-1413.	1.7	7
68	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	3.2	7
69	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	2.3	6
70	The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. <i>PLoS ONE</i> , 2020, 15, e0229063.	2.5	6
71	Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. <i>Neoplasia</i> , 2021, 23, 859-869.	5.3	6
72	A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2511-2511.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. <i>Discovery Medicine</i> , 2014, 18, 323-30.	0.5	6
74	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
75	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 75.	2.0	5
76	Is There Any Reason to Delay Introduction of Tumor Necrosis Factor in the Management of In-Transit Metastasis of Unresectable Melanoma?. <i>Journal of Clinical Oncology</i> , 2007, 25, 1149-1149.	1.6	4
77	Therapeutic Targeting of Autophagy in Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 709-718.	1.5	4
78	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2520-2520.	1.6	4
79	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. <i>Oncoscience</i> , 2015, 2, 285-293.	2.2	4
80	Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 144-150.	4.9	4
81	Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. <i>ESMO Open</i> , 2019, 4, e000539.	4.5	3
82	Emerging Treatment Strategies in Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 773-787.	1.1	3
83	A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. <i>ACG Case Reports Journal</i> , 2017, 4, e34.	0.4	3
84	Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 268-275.	4.9	3
85	The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 492-500.	1.3	3
86	MRI Evaluation of Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 191-193.	27.0	2
87	Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 183-185.	2.4	2
88	Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?. <i>Journal of Clinical Oncology</i> , 2012, 30, 892-893.	1.6	2
89	Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 11-14.	1.4	2
90	Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 175-182.	0.5	2

#	ARTICLE	IF	CITATIONS
91	(OA44) Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, e18-e19.	0.8	2
92	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€“Deficient Pancreatic Cancer After Planned Treatment Interruption. <i>JCO Precision Oncology</i> , 2020, 4, 780-784.	3.0	2
93	The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 291-291.	1.6	2
94	Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 792-792.	1.6	2
95	Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 796-802.	1.1	1
96	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. <i>Blood</i> , 2013, 122, 3048-3048.	1.4	1
97	Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 404-404.	1.6	1
98	A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 330-330.	1.6	1
99	Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.. <i>Journal of Clinical Oncology</i> , 2019, 37, 69-69.	1.6	1
100	The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 419-419.	1.6	1
101	Cancer Immunotherapy in the Immunosuppressed Patients and Its Relevance to Clinical Practice. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 127-128.	1.4	1
102	A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 39-39.	1.6	1
103	A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. <i>Annals of Oncology</i> , 2016, 27, vi367.	1.2	0
104	Multi-agent Induction Chemotherapy Followed by Chemoradiation is Associated With Improved Survival Compared to Chemotherapy Alone in Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E193-E194.	0.8	0
105	Prognostic Factors Affecting Overall Survival in Non-metastatic, Primary Squamous Cell Carcinoma of the Pancreas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, E31-E32.	0.8	0
106	Abstract 2773: Clinical outcomes of patients with head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. , 2010, , .		0
107	Abstract 2264: K-ras mutations in colorectal cancer may predict a pattern of organ-specific metastasis. , 2011, , .		0
108	Abstract 1279: Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
109	Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS4596-TPS4596.	1.6	0
110	Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012.. Journal of Clinical Oncology, 2015, 33, 687-687.	1.6	0
111	Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012.. Journal of Clinical Oncology, 2015, 33, 311-311.	1.6	0
112	Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy.. Journal of Clinical Oncology, 2015, 33, 1526-1526.	1.6	0
113	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584.	1.6	0
114	Abstract B93: A data base of N of 1 case reports from pancreatic cancer patients enrolled in First-in-man studies 2002 through 2012. , 2015, , .		0
115	Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma. , 2015, , .		0
116	The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 111-111.	1.6	0
117	A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS524-TPS524.	1.6	0
118	Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 97-97.	1.6	0
119	Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series. Journal of Immunotherapy and Precision Oncology, 2018, 1, 1-6.	1.4	0
120	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. Journal of Immunotherapy and Precision Oncology, 2020, 3, 137-139.	1.4	0
121	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discovery Medicine, 2015, 19, 101-8.	0.5	0